OKUR NASDAQ
OnKure Therapeutics, Inc.
1W: -11.7%
1M: -27.7%
3M: -44.4%
YTD: -13.5%
1Y: -4.1%
3Y: -96.6%
5Y: -97.0%
$2.56
+0.02 (+0.79%)
Weekly Expected Move ±7.5%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$103.7M
52W Range2.23-5.38
Volume526,929
Avg Volume286,765
Beta0.30
Dividend—
Analyst Ratings
Company Info
CEONicholas A. Saccomano
Employees45
SectorHealthcare
IndustryBiotechnology
IPO Date2021-04-08
Websiteonkuretherapeutics.com
6707 Winchester Circle
Boulder, CO 80301
US
Boulder, CO 80301
US
720 307 2892
About OnKure Therapeutics, Inc.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Latest News
OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37
[10-Q] OnKure Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
OnKure Therapeutics Reports First Quarter 2026 Financial Results
CVS Q1 Earnings Preview: Health Services Likely to Lead Performance
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Saccomano Nicholas A | S-Sale | 87 | $2.97 | 2026-09-21 |
| Leverone Jason A. | S-Sale | 302 | $2.97 | 2026-09-21 |
| Manke Isaac | 0 | — | 2026-08-07 | |
| Carruthers R Michael | A-Award | 22,350 | $4.14 | 2026-08-07 |
| Saccomano Nicholas A | A-Award | 150,000 | $4.14 | 2026-08-07 |